Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Ben Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The Business And Science Of Obesity With Roger Cone, Ph.D., Founder Of Courage Therapeutics

54:23
 
Share
 

Manage episode 494362066 series 2739469
Content provided by Ben Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We love to hear from our listeners. Send us a message.

On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO.
This episode of the Business of Biotech is brought to you by Ecolab.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  continue reading

Chapters

1. Episode Introduction (00:00:00)

2. Discovering the Melanocortin System (00:07:44)

3. Evolution of Obesity Treatments (00:20:45)

4. From Academia to Biotech Ventures (00:36:44)

5. Courage Therapeutics Development Pipeline (00:43:08)

6. Synergies with GLP-1 Therapies (00:48:01)

270 episodes

Artwork
iconShare
 
Manage episode 494362066 series 2739469
Content provided by Ben Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We love to hear from our listeners. Send us a message.

On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO.
This episode of the Business of Biotech is brought to you by Ecolab.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

  continue reading

Chapters

1. Episode Introduction (00:00:00)

2. Discovering the Melanocortin System (00:07:44)

3. Evolution of Obesity Treatments (00:20:45)

4. From Academia to Biotech Ventures (00:36:44)

5. Courage Therapeutics Development Pipeline (00:43:08)

6. Synergies with GLP-1 Therapies (00:48:01)

270 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play